Abstract
Coronavirus disease 2019 (COVID-19) is a highly contagious viral disease causing a Severe Acute Respiratory distress syndrome. In 392 consecutive COVID-19 patients hospitalized in IRCCS San Raffaele in Milan (age 67 years range 28-94, Sex M, 74,7%) from march 2 until 25 April 2020, renal function was monitored. History of Hypertension (HYP) was the main comorbidity factors (58 %) under drug medications in 86.1% (ACEi/ARB 56,5). AKI (any stage) was detected in 6.2% of patients at emergency department (ED) admission. Baseline kidney function and HYP were the main determinants of ED-AKI (ED-AKI in HYP 89.5% vs 56.4 % in non-HYP; p=0.004) with an increased risk of 4.98 (95% CI 1.04-23.80; p=0.044) after adjustment by independent covariates, including age and respiratory distress.Moreover, MBP levels at presentation were inversely related with increased risk of ED-AKI. A stand-alone level of MBP < 86 mmHg (i.e.< 120/70 mmHg) or <65 mmHg at presentation were independently associated with increased risk of AD-AKI of 3.95 (95% CI 1.41-11.04, p=0.009) or 9.13 (95% CI 1.40-59.77; p=0.021), respectively. Nevertheless, no relationship between MBP and severity of respiratory distress was observed. No effect of any specific chronically used antihypertensive pharmacologic treatment was observed. During hospitalization AKI (H-AKI) occurred in 34.7% of patients; the median time to AKI development was 7 days (IQR 3-12 days). The incidence of H-AKI was significantly higher in elderly patients (age > 65 yrs; 42.5% vs 24.3 %, X 2 16.62; p<0.0001) or with HYP (43.4% vs 20.6 %, X 2 21.57; p<0.0001). Survival analysis showed that age over 65 years, HYP and severity of respiratory distress were main determinant of H-AKI. However, in a model of univariate Cox regression, only age above 65 years, COPD, CKD stage 3-5, HYP, MPB<86 mmHg at ED admission, and severity of illness were independently associated with twice increase of overall in-hospital mortality.In conclusion, we observed that history of Hypertension, CKD and hypotension at the presentation are important risk factor for ED-AKI and mortality in patients with COVID-19 infection. Early reduction of antihypertensive therapy if blood pressure is lower than 120/70 may decrease AKI development and mortality in COVID19.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have